Corporate News

Confirmation of detection of Omicron variant

10 January 2022

VISITECT® COVID-19 antigen test performs with the same high accuracy on the Omicron variant

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, notes concerns regarding the ability of certain lateral flow tests to detect the Omicron variant with the same sensitivity for lower viral loads.

Further to the announcement on 14 December 2021, the Company’s technology partner Mologic Ltd (“Mologic”) has today re-confirmed that the Mologic Covios® Ag lateral flow test, performs with the same high accuracy on the Omicron variant as it does with existing known variants.

Mologic’s studies are ongoing to determine the absolute performance of the test across the use case settings and in laboratory environments to produce a comprehensive analysis of the detection of Omicron. No data exists to suggest there is an issue, be that in silico or in trials.

This is the same test that is manufactured and sold for professional use by Omega as the VISITECT® COVID-19 antigen test.


Omega Diagnostics Group PLC
Colin King, Chief Executive Officervia Walbrook PR
Chris Lea, Chief Financial Officer  
finnCap LtdTel: 020 7220 0500
Geoff Nash/Edward Whiley (Corporate Finance)  
Alice Lane/ Charlotte Sutcliffe (ECM)  
Walbrook PR Limited Tel: 020 7933 8780 or [email protected]
Paul McManus Mob: 07980 541 893
Lianne Applegarth Mob: 07584 391 303
Sam Allen Mob: 07502 558 258

About Omega Diagnostics Group PLC 

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health. 

Sign up for Investor Alerts